Fig. 2. OS of CN-AML patients according to PHB2 protein overexpression (IHCS score ≥6). The five-yr OS rate in the group of patients overexpressing PHB2 is a significant 22.5% lower than that in the group of patients with normal PHB2 expression.
Abbreviations: PHB2, prohibitin 2; OS, overall survival; CN-AML, cytogenetically normal acute myeloid leukemia; IHCS, immunohistochemical staining.

Ann Lab Med 2022;42:585~589 https://doi.org/10.3343/alm.2022.42.5.585